Study
| Investigator-initiated, open-label, single-arm, multi-institutional, phase II trial (TAB) |
| Adult patients with HER2-positive, treatment-naïve BTCs |
| Trastuzumab + Gemcitabine + Cisplatin (n=90) |
Efficacy
| ORR: 55.7% [50 of 90 pts] |
| mPFS: 7.0 mos [6.2-7.8] |
| 12 mos PFS: 17.6% [16.7-18.5] |
| mOS: 9.96 mos [9.25-10.66] |
| 12 mos OS: 39.1% [27.3-50.9] |
Safety
| Grade3: Anemia (29%), neutropenia (20%), aminotransferases elevation (18%), fatigue (17%) |
Jour of Clin Oncol NOV 09, 2023
http://doi.org/10.1200/JCO.23.01193
Reviewed by Elvin Chalabiyev, MD on Nov 20, 2023
